Fast Track Group (CRNX) key performance indicators and operating metrics (12 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Unique Prescribers | 263.00 | FY2026-Q1 |
| Enrollment Forms | 232.00 | FY2026-Q1 |
| Patients on Reimbursed Therapy | 70.00 percent | FY2026-Q2 |
| Net Product Revenue | 24.04M | FY2026-Q2 |
| Reimbursed Filled Prescriptions | 50.00 percent | FY2025-Q4 |
| Community Prescriber Share | 70.00 percent | FY2026-Q1 |
| Collaboration and License Revenue | 1.08M | FY2026-Q2 |
| Cash, Cash Equivalents and Investments | 1.3B | FY2026-Q1 |
| Licensing Agreement Revenue | 400K | FY2026-Q1 |
| Investigator-Assessed Progression-Free Survival Rate | 74.00 percent | FY2025-Q4 |
| Fully Diluted Share Count | 123.5M | FY2026-Q1 |
| Reportable revenue | 143K | FY2025-Q3 |
Back to CRNX overview · CRNX earnings · CRNX holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.